SCHEMBL118020

SCHEMBL118020

O=c1ccc2ccc3occcc3c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
FTO Q9C0B1 1/20 0.40
NFKB1 P19838 1/20 0.39
ALDH1A1 P00352 11/20 0.37
KDM4E B2RXH2 8/20 0.37
HPGD P15428 5/20 0.37
ELANE P08246 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PGR P06401 1/20 0.34
LMNA P02545 3/20 0.34
DYRK1A Q13627 1/20 0.33
KMT2A Q03164 6/20 0.32
MEN1 O00255 5/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
GAA P10253 2/20 0.32
HTT P42858 2/20 0.32
RAB9A P51151 1/20 0.32
TSHR P16473 3/20 0.32
PKM P14618 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5153688 0.78 LMNA (0.44) MAOAMAOBFTONFKB1ALDH1A1
SCHEMBL6708105 0.73 ALDH1A1 (0.43) MAOAMAOBFTOALDH1A1KDM4E
SCHEMBL10746966 0.72 KDM4E (0.40) ALDH1A1KDM4EHPGDLMNAKMT2A
SCHEMBL6421629 0.72 MAOA (0.33) MAOAMAOBFTOALDH1A1KDM4E
SCHEMBL5407353 0.71 POLB (0.44) MAOAMAOBFTOALDH1A1KDM4E
SCHEMBL29588824 0.71 MAPK10 (0.42) MAOAMAOBFTOALDH1A1KDM4E
SCHEMBL4495841 0.71 MAPK10 (0.42) MAOAMAOBFTOALDH1A1KDM4E
SCHEMBL4725062 0.71 SMN1; SMN2 (0.33) MAOAMAOBFTONFKB1ALDH1A1
SCHEMBL28747394 0.71 RCE1 (0.35) MAOAMAOBFTONFKB1ALDH1A1
SCHEMBL3295735 0.69 ALDH1A1 (0.37) MAOAMAOBFTOALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116036083-B Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer 江西省林业科学院 2023-06-02 CN claimed
CN-116036083-A Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer 江西省林业科学院 2023-05-02 CN claimed
US-20210251961-A1 COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME ALLERGAN INC (US) 2021-08-19 US claimed
EP-1654002-B1 COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING THE SAME ALLERGAN INC (US) 2009-10-07 EP claimed
EP-1654002-A2 COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING THE SAME Allergan, Inc. (US) 2006-05-10 EP claimed
WO-2005014046-A2 COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING THE SAME ALLERGAN, INC. (US) 2005-02-17 WO claimed
US-20050031697-A1 Compositions for delivery of therapeutics into the eyes and methods for making and using same ALLERGAN, INC. (US) 2005-02-10 US claimed
CN-114891011-B Preparation method of medical intermediate 2-amino-tetrahydropyran [3,2-c ] quinoline-5-one derivative 南京苏亦欣医药科技有限公司 2025-01-17 CN disclosed
CN-118496286-A Chemical synthesis method of vibrio vulnificus organism type 2A serotype O-antigen disaccharide fragment 江南大学 2024-08-16 CN disclosed
CN-116036083-B Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer 江西省林业科学院 2023-06-02 CN disclosed
CN-116036083-B Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer 江西省林业科学院 2023-06-02 CN disclosed
CN-116036083-B Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer 江西省林业科学院 2023-06-02 CN disclosed
CN-116036083-A Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer 江西省林业科学院 2023-05-02 CN disclosed
US-4760072-A Crystalline and contains bound water; treats reversible obstructive condition of airways in a mammal FISONS, PLC (GB) 1988-07-26 US disclosed
EP-0030423-B1 A PROCESS FOR THE PRODUCTION OF 1,4-DIHYDRO-4-OXO-QUINOLINE-2-CARBOXYLIC ACIDS, OR SALTS, ESTERS OR AMIDES THEREOF AND INTERMEDIATES THEREFOR FISONS plc (GB) 1985-02-13 EP disclosed
US-4474787-A 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof FISONS LIMITED (GB) 1984-10-02 US disclosed
US-4419352-A ANTIALLERGENS; ANTI SECRETORY AGENTS; MUCUS FISONS LIMITED (GB) 1983-12-06 US disclosed
US-4414416-A Certain diacetyl-amino-phenolic derivatives FISONS LIMITED (GB) 1983-11-08 US disclosed
US-4328341-A Process for preparing certain pyrano[3,2-g]quinoline 2,8-dicarboxylates and 4-oxo-quinoline-2-carboxylates FISONS LIMITED (GB) 1982-05-04 US disclosed
EP-0030423-A1 A process for the production of 1,4-dihydro-4-oxo-quinoline-2-carboxylic acids, or salts, esters or amides thereof and intermediates therefor FISONS plc (GB) 1981-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050031697-A1 Compositions for delivery of therapeutics into the eyes and methods for making and using same MUC1, EPCAM, MYOC MAOA 3233/4885MAOB 3737/4885FTO 4858/4885
US-20210251961-A1 COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME MUC1, EPCAM, MYOC MAOA 3324/4885MAOB 3764/4885FTO 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.